History. Expertise. Performance.

Raglan Capital was established in 2007 by Cathal Friel with a number of former Merrion Stockbrokers colleagues following the successful sale of Merrion Stockbrokers in 2006. Its initial aim was to continue providing corporate finance services as previously done with Merrion to a range of Irish and international clients. However, from day one it was also Raglan’s stated intention of looking to create companies in-house which are then listed on the London Stock Exchange, working on occasion in conjunction with former clients of Raglan’s corporate finance services whom they advised during successful trade sales i.e. entrepreneurs who had sold their companies and wanted to do it all again but in a publicly listed vehicle. Therefore from 2012 onwards, we wound down the corporate finance advisory business to focus almost exclusively on creating our own in-house companies.

Samuel Beckett Bridge

Advisory

Corporate Finance Advisor

  • Raglan associate company Amryt on securing a €20m debt facility from the EIB.

Advisor on in-licensing of Lojuxta

  • Assisted associate company Amryt Pharma on acquiring the EMEA rights from Aegerion Pharmaceuticals

Corporate Finance Advisor

  • Advised on the farm-out to SK Innovation of a 12.5% interest in the Foum Assaka licence, offshore Morocco

Corporate Finance Advisor

  • Advised on its £10m IPO on the AIM market of the London Stock Exchange

Corporate Finance Advisor

  • Advised on its Reverse Take Over of Sterling Green Group plc

Corporate Finance Advisor

  • Raglan associate company Amryt on securing a €20m debt facility from the EIB.

Advisor on in-licensing of Lojuxta

  • Assisted associate company Amryt Pharma on acquiring the EMEA rights from Aegerion Pharmaceuticals

Corporate Finance Advisor

  • Advised on the farm-out to SK Innovation of a 12.5% interest in the Foum Assaka licence, offshore Morocco

Corporate Finance Advisor

  • Advised on its £10m IPO on the AIM market of the London Stock Exchange

Corporate Finance Advisor

  • Advised on its Reverse Take Over of Sterling Green Group plc

Corporate Finance Advisor

  • Raglan associate company Amryt on securing a €20m debt facility from the EIB.

Advisor on in-licensing of Lojuxta

  • Assisted associate company Amryt Pharma on acquiring the EMEA rights from Aegerion Pharmaceuticals

Corporate Finance Advisor

  • Advised on the farm-out to SK Innovation of a 12.5% interest in the Foum Assaka licence, offshore Morocco

Corporate Finance Advisor

  • Advised on its £10m IPO on the AIM market of the London Stock Exchange

Corporate Finance Advisor

  • Advised on its Reverse Take Over of Sterling Green Group plc

Trade Sales

Corporate Finance Advisor

  • Raglan associate company Amryt on securing a €20m debt facility from the EIB.

Advisor on in-licensing of Lojuxta

  • Assisted associate company Amryt Pharma on acquiring the EMEA rights from Aegerion Pharmaceuticals

Corporate Finance Advisor

  • Advised on the farm-out to SK Innovation of a 12.5% interest in the Foum Assaka licence, offshore Morocco

Corporate Finance Advisor

  • Advised on its £10m IPO on the AIM market of the London Stock Exchange

Corporate Finance Advisor

  • Advised on its Reverse Take Over of Sterling Green Group plc

Corporate Finance Advisor

  • Raglan associate company Amryt on securing a €20m debt facility from the EIB.

Advisor on in-licensing of Lojuxta

  • Assisted associate company Amryt Pharma on acquiring the EMEA rights from Aegerion Pharmaceuticals

Corporate Finance Advisor

  • Advised on the farm-out to SK Innovation of a 12.5% interest in the Foum Assaka licence, offshore Morocco

Corporate Finance Advisor

  • Advised on its £10m IPO on the AIM market of the London Stock Exchange

Corporate Finance Advisor

  • Advised on its Reverse Take Over of Sterling Green Group plc

Corporate Finance Advisor

  • Raglan associate company Amryt on securing a €20m debt facility from the EIB.

Advisor on in-licensing of Lojuxta

  • Assisted associate company Amryt Pharma on acquiring the EMEA rights from Aegerion Pharmaceuticals

Corporate Finance Advisor

  • Advised on the farm-out to SK Innovation of a 12.5% interest in the Foum Assaka licence, offshore Morocco

Corporate Finance Advisor

  • Advised on its £10m IPO on the AIM market of the London Stock Exchange

Corporate Finance Advisor

  • Advised on its Reverse Take Over of Sterling Green Group plc

Fundraising

Corporate Finance Advisor

  • Raglan associate company Amryt on securing a €20m debt facility from the EIB.

Advisor on in-licensing of Lojuxta

  • Assisted associate company Amryt Pharma on acquiring the EMEA rights from Aegerion Pharmaceuticals

Corporate Finance Advisor

  • Advised on the farm-out to SK Innovation of a 12.5% interest in the Foum Assaka licence, offshore Morocco

Corporate Finance Advisor

  • Advised on its £10m IPO on the AIM market of the London Stock Exchange

Corporate Finance Advisor

  • Advised on its Reverse Take Over of Sterling Green Group plc

Corporate Finance Advisor

  • Raglan associate company Amryt on securing a €20m debt facility from the EIB.

Advisor on in-licensing of Lojuxta

  • Assisted associate company Amryt Pharma on acquiring the EMEA rights from Aegerion Pharmaceuticals

Corporate Finance Advisor

  • Advised on the farm-out to SK Innovation of a 12.5% interest in the Foum Assaka licence, offshore Morocco

Corporate Finance Advisor

  • Advised on its £10m IPO on the AIM market of the London Stock Exchange

Corporate Finance Advisor

  • Advised on its Reverse Take Over of Sterling Green Group plc

Corporate Finance Advisor

  • Raglan associate company Amryt on securing a €20m debt facility from the EIB.

Advisor on in-licensing of Lojuxta

  • Assisted associate company Amryt Pharma on acquiring the EMEA rights from Aegerion Pharmaceuticals

Corporate Finance Advisor

  • Advised on the farm-out to SK Innovation of a 12.5% interest in the Foum Assaka licence, offshore Morocco

Corporate Finance Advisor

  • Advised on its £10m IPO on the AIM market of the London Stock Exchange

Corporate Finance Advisor

  • Advised on its Reverse Take Over of Sterling Green Group plc

The above list includes some transactions completed by Raglan Directors prior to joining Raglan.

Our IPO Companies

Poolbeg Pharma plc

  • Spun out of Open Orphan & listed on AIM in July 2021. Commenced trading on OTCQB in the US in March 2022.

hVIVO plc

  • Listed on the AIM and Euronext exchanges in June 2019 through the reverse takeover of Venn Life Sciences and acquired hVIVO plc in January 2020.

Amryt Pharma plc

  • Listed on the London AIM and Dublin Euronext exchanges in 2016, raising £20m in funding. Now listed on NASDAQ.

Fastnet Oil and Gas

  • Raised over $50m through its floatation on the London and Dublin stock exchanges.

European Green Metals

  • European Green Metals (EGM) is a privately-owned mineral exploration company with a focus on Europe.